Radiopharmaceuticals are radioactive drugs used in nuclear medicine for both diagnostics and therapeutics purposes. These play a crucial role in medical imaging techniques through emission of nuclear radiation such as gamma rays from radioactive tracers introduced into the body. Radiopharmaceuticals consist of radioactive isotopes bonded to bioactive pharmaceutical compounds like monoclonal antibodies to selectively target tissues, organs or cells. On interaction with gamma cameras during scans, these help physicians gain functional insights into metabolic, physiological and anatomical details non-invasively. Rising prevalence of chronic diseases, growing geriatric population susceptible to cancer and cardiac ailments and technological advancements in radiotracers can drive the growth of radiopharmaceuticals market.

Market Dynamics:

Surging demand for early disease diagnosis, favorable reimbursement policies, increasing healthcare expenditure, and awareness about benefits of nuclear medicine procedures can drive the radiopharmaceuticals in nuclear medicine market. However, short half-lives of radiotracers requiring on-site production facilities and high installation and maintenance costs of equipment can hamper the market growth. Developing new radiotracers for neurology, rare diseases and personalized medicine through R&D collaborations can offer growth opportunities. Emerging applications in drug development and targeted radiotherapy can also drive the market growth.

Key Features of the Study:

• This report provides in-depth analysis of the global radiopharmaceuticals in nuclear medicine market, and provides market size (USD billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global radiopharmaceuticals in nuclear medicine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GE Healthcare, Bracco Imaging S.p.A., Lantheus Medical Imaging Inc., Bayer AG, Novartis AG (Advanced Accelerator Applications), Nordion Inc., and Jubilant DraxImage Inc. dba Jubilant Radiopharma
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global radiopharmaceuticals in nuclear medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global radiopharmaceuticals in nuclear medicine market

Detailed Segmentation-

• By Product Type
• • Diagnostic Nuclear Medicine
    • SPECT Radiopharmaceuticals
    • PET Radiopharmaceuticals
  • Therapeutic Nuclear Medicine
• By Application
• • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Others
• By End User
• • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Diagnostic Centers
  • Others
• By Region           
• • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
• • Progenics Pharmaceuticals, Inc.
  • NorthStar Medical Radioisotopes LLC
  • Curium Pharma
  • Life Molecular Imaging
  • Lantheus Holdings, Inc.
  • Cardinal Health, Inc.
  • General Electric Company
  • Bracco S.p.A.
  • Bayer AG
  • GE Healthcare
  • Jubilant Pharmova Limited
  • Eckert & Ziegler
  • Mallinckrodt
  • NTP Radioisotopes SOC Ltd.
  • Telix Pharmaceuticals, Inc.
  • Nordic Nanovector
  • Y-mAbs Therapeutics, Inc.
  • Siemens Healthineers AG